Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 21 -30 of 135 Show results per page	View Search Criteria \| Help With Results


21.		Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 70				Other				Eudract-2005-003911-63 PEI 119/01, NCT00311857


22.		AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				021-003 NCT00394628


23.		Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				9815 H6Q-MC-S008, NCT00402116

Last Modified: 7/24/2007 First Published: 6/8/2007


24.		Phase I/II Study of Hydroxychloroquine, Radiotherapy, and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				NABTT-0603 NABTT-0603, 0603, NCT00486603


25.		Aerosol L9-NC and Temozolomide in Ewing's Sarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				10 and over				Other				2005-0889 NCT00492141

Last Modified: 10/2/2007 First Published: 8/10/2007


26.		Phase I/II Study of VNP40101M and Temozolomide in Patients With Progressive or Relapsed Malignant Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				Over 18				NCI				NU07C1 NU 07C1, NCT00516282


27.		DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				2005-0135 NCT00515788


28.		Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				2004-0595 NCT00527657

Last Modified: 6/12/2008 First Published: 2/27/2008


29.		Phase I/II Randomized Study of Cytomegalovirus-Specific T-Cell Adoptive Transfer in Patients With Newly Diagnosed Glioblastoma Multiforme Who Are Recovering From Therapeutic Temozolomide-Induced Lymphopenia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Diagnostic, Treatment				Active				18 and over				NCI				DUMC-PRO00000580 PRO00000580, DUMC-SPORE Project 3, NCT00627224

Last Modified: 8/26/2008 First Published: 2/27/2008


30.		Phase I/II Randomized Study of Standard Chemoradiotherapy Followed by PEP-3-KLH Conjugate Vaccine With Versus Without Daclizumab in Patients With Resected Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				DUMC-PRO00000947 PRO00000947, DUMC-SPORE II 2003 CMV Grant, NCT00626015

Select All on One Page


					< Previous 1 2 3 4 5 6 Next >

| | | | | | | |

A Service of the National Cancer Institute